Literature DB >> 20352163

Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.

Daniel Bolliger1, Fania Szlam, Nobuaki Suzuki, Tadashi Matsushita, Kenichi A Tanaka.   

Abstract

Decreased levels of factor VIII (FVIII) limit the amount of thrombin generated at the site of injury, but not the rate that thrombin is neutralised by antithrombin (AT). We hypothesised that FVIII-deficient mice with heterozygous AT deficiency will demonstrate increased thrombin generation and therefore less in vivo bleeding compared to FVIII-deficient mice with normal AT levels. Therefore, we performed tail bleeding experiments in wild-type (WT), heterozygous AT deficient (AT(+/-)) mice, FVIII-deficient (FVIII(-/-)) mice, and FVIII-deficient mice with heterozygous AT deficiency (FVIII(-/-)/AT(+/-)). Amount of bleeding was assessed by measuring absorbance of haemoglobin released from lysed red blood cells collected after tail transection. In addition, we measured thrombin generation, activated partial thromboplastin time (aPTT), and AT activity in plasma from the different mice groups. Tail bleeding was significantly reduced in FVIII(-/-)/AT(+/-) mice compared to FVIII(-/-) mice. On the other hand, there was no difference in tail bleeding between AT(+/-) and wild-type mice. Thrombin generation was dependent on the mice genotype, and increased in the following order: FVIII(-/-) < FVIII(-/-)/AT(+/-) < WT < AT(+/-). The aPTT was not influenced by reduced AT activity (i.e. AT(+/-) genotype), but was significantly prolonged in FVIII(-/-) and FVIII(-/-)/AT(+/-) mice. Using FVIII-deficient mice as an in vivo murine model of reduced thrombin generation, we demonstrated that moderately reduced AT levels increase thrombin generation and decrease bleeding after traumatic tail vessel injury. In agreement with congenital thrombotic conditions, our data elucidate that bleeding phenotypes can be modulated by the balance between procoagulant and anticoagulant proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352163     DOI: 10.1160/TH09-10-0732

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

Review 2.  Non-factor replacement therapy for haemophilia: a current update.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2018-02-14       Impact factor: 3.443

3.  Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice.

Authors:  Yang Liu; Nicole L Jennings; Anthony M Dart; Xiao-Jun Du
Journal:  World J Exp Med       Date:  2012-04-20

4.  Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

Authors:  T J Girard; N M Lasky; K Grunz; G J Broze
Journal:  J Thromb Haemost       Date:  2018-12-16       Impact factor: 5.824

Review 5.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

Review 6.  Novel treatments for hemophilia through rebalancing of the coagulation cascade.

Authors:  Yakun Zhao; Angela C Weyand; Jordan A Shavit
Journal:  Pediatr Blood Cancer       Date:  2021-02-12       Impact factor: 3.167

Review 7.  Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.

Authors:  Maricel G Miguelino; Jerry S Powell
Journal:  Patient Prefer Adherence       Date:  2014-08-08       Impact factor: 2.711

Review 8.  An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B.

Authors:  Nicoletta Machin; Margaret V Ragni
Journal:  J Blood Med       Date:  2018-08-22

Review 9.  Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options.

Authors:  Katherine Regling; Michael U Callaghan; Robert Sidonio
Journal:  Pediatric Health Med Ther       Date:  2022-02-15

Review 10.  Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Authors:  Steven P Grover; Nigel Mackman
Journal:  Front Cardiovasc Med       Date:  2022-05-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.